608 results about "Cerebral ischaemia" patented technology

The invention discloses a halogen substituted 2-(a-hydroxyl amyl) benzoate compound, a preparation method and medicinal application thereof, which belong to the technical field of organic chemical synthesis. The structural formula of the compound which is showed as above has an antimer structure, wherein <R1> represents a halogen atom; n is equal to 1 to 3; and M represents a univalent metallic ion or a bivalent metallic ion or a trivalent metallic ion or an organic base. The compound has the advantages of better activity on preventing and treating cardio-cerebral ischemia diseases, improving cardio-cerebral circulation disturbance and resisting thrombus, and the like.

The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.

Present invention features methods for induction of angiogenesis by administration of lysine (l-&d-) or lysine oligomers (molecular weight approx between 500 and 2500), both homo and hetero-oligomers, consisting of either l-or d- or both enantiomers. Induction of Angiogenesis by the methods of the invention can be use in therapeutic angiogenesis, in, for example, treatment of ischaemic conditions and syndromes, such as chronic wounds (e.g diabetic wounds and ulcers, bed sores and other pressure sores, burns of various degrees and extents etc.) as well as coronary and cerebral ischaemia and peripheral vascular ischaemic conditions. Induction of angiogenesis by the described methods also will be useful in inducing/enhancing radiosesitivity in some solid tumors.

The present invention relates to a method for the treatment of cerebral ischaemia and a drug for the treatment of cerebral ischaemia in particular in humans, as occurs for example in the case of stroke patients. It was found surprisingly that peripheral administering of erythropoietin to the cerebral tissue affected by the ischaemia has a distinctly protective effect. Erythropoietin has the effect thereby that the region of the cerebral tissue which is damaged permanently, in particular in the penumbra, is dramatically reduced relative to conventional measures in the case of cerebral ischaemia without erythropoietin administration.

The invention provides a pharmaceutical composition useful in treating cerebral ischemia and cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.

The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):

X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  I

• • or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention relates to the compounds of the formula (I) and salts thereof (all the symbols are the same meanings as described in the specification).The compounds of the formula (I) possess inhibitory activity of N-type calcium channel, so they are useful as drug for prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis, epilepsy, asthma and pollakiuria etc. or agent for the treatment of pain.

The invention discloses two types of flavonoid glycoside compounds which are kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(2'' ', 4'' '-O-diacetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-glucopyrose galactopyranoside and kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(4'' '-O-acetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-D-glucopyrose galactopyranoside respectively. The invention also discloses a method for preparing the two types of flavonoid glycoside compounds. Moreover, pharmacological tests prove that the two types of flavonoid glycoside compounds have quite good effects of reducing blood sugar and blood fat and resisting oxidation and cerebral ischemia, and thus, the flavonoid glycoside compounds of the invention can be used for preparing medicaments, food and cosmetics for preventing and treating diabetes, reducing blood fat and resisting oxidation and cerebral ischemia.

The present invention provides one new kind of glycyrrhetic acid derivative with high water solubility, high absorption, no irritation to blood vessel and capacity of being prepared into injection, and its preparation process, medicinal composition and preparation. The glycyrrhetic acid derivative has excellent treating effect on acute and chronic hepatitis, bacterial hepatitis, viral hepatitis, cerebral ischemia/re-perfusion damage, brain injury and myocardial ischemia/re-perfusion damage.

The invention relates to the field of natural drug and medicinal chemistry, in particular to ursane-type pentacyclic triterpenoid amino acid derivatives (I), and the preparation method and the medicinal application thereof. The compounds have effect on inhibiting glycogen phosphorylase, and can be used for preparing drugs for resisting diabetes, cerebral ischemia, cardiovascular diseases, hyperlipemia, obesity, atherosclerosis and tumor. The invention also relates to the preparation method of the compounds and drug preparations containing the compounds.

The invention discloses a PEGylated scutellarin compound and a preparation method thereof. The PEGylated scutellarin compound is as the shown formula (IV) and the PEGylated scutellarin compound can be applied to preparing medicaments applied to treating cerebral thrombosis, cerebral infarction, cerebral apoplexy, sequelaes caused by cerebral apoplexy, coronary heart disease or angina. Compared with the original scutellarin compound, the water solubility of the scutellarin compound is increased obviously; simultaneously, pharmacodynamics experiment on the mice model of cerebral ischemia-reperfusion shows that: compared with the original medicament, the biological activity of the scutellarin promedicament is strengthened obviously.

The present invention is kinder leaf total flavone extract and its preparation process and application, and features that the kinder leaf total flavone extract contains total flavone in 50-95 %, including rutin 0.2-30.0 %, hyperin 0.5-30.0 %, isoquercitrin 10.0-30.0 %, trifolin 3.0-20.0 %, astragaloside 2.0-5.0 %, 6''-O-acetyl isoquercitrin 1.0-6.0 %, quercitrin 0.5-4.0 %, trifolitin 0.2-3.0 %, etc. The kinder leaf total flavone extract is applied in preparing medicine for treating cardiac and cerebral ischemia.

The present invention discloses a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases which comprises Radix Salviae Miltiorrhizae extract 5.0%-70.0%, Radix Notoginseng extract 10.0%-85.0%, Radix Astragali extract 5.0%-70.0%, and Bomeol or oil of Lignum Dalbergiae Odoriferae 1.0%-15.0%. The composition is active against cerebral ischemia and myocardial ischemia. The effects are superior to total phenic acid of Radix Salviae Miltiorrhizae or total saponin of Radix Notoginseng respectively, or the combination thereof. The composition of the invention can provide various kinds of preparations by the addition of various accessories. Thus the invention provides a more effective and convenient composition of TCM effective sections and its preparations.

The invention provides an acute cerebral ischemia image segmentation model training method and an acute cerebral ischemia image segmentation method. The method comprises steps that magnetic resonance image data is acquired, and brain tissue images are extracted; normalization operation of the extracted brain tissue images is carried out; ischemic areas of the extracted brain tissue images are acquired as a positive sample, and expansion of the positive sample is carried out according to a set expansion coefficient to acquire data which is taken as a negative sample; characteristic vectors are respectively extracted from magnetic resonance images T2, DWI and ADC, the positive sample and the negative sample of asymmetric maps ASM, and normalization processing on the characteristic vectors is carried out; based on the characteristic vectors after normalization processing, an acute cerebral ischemia segmentation model is acquired through an SVM classifier. The method is advantaged in that the provided acute cerebral ischemia segmentation model can be applied to ischemic area segmentation, a segmentation speed is fast, and high accuracy is realized.

The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and/or neurological dysfunction and/or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.

The invention relates to the field of research into pharmaceutical chemistry, and particularly discloses a novel aromatic acid pro-drug with nitrogen monoxide donor, and a preparation method and application thereof in preventing and treating thrombotic diseases. In the invention, natural aromatic acid compounds with strong antithrombotic actions are structurally modified, and the carboxylic acid groups are incorporated with nitrogen monoxide donor to obtain the nitrogen monoxide donor type aromatic acid pro-drug with favorable liposolubility. The aromatic acid pro-drug with nitrogen monoxide donor has favorable solubility, can effectively permeate into the biomembrane lipid bimolecular layer, and can enhance the bioavailability after the human body takes the pro-drug. The pro-drug can be resolved into aromatic acid compounds and release nitrogen monoxide, and the aromatic acid compounds and nitrogen monoxide can cooperate to perform the pharmacological activities of resisting thrombi, resisting platelet aggregation and the like. The aromatic acid pro-drug with nitrogen monoxide donor can be used for preventing and treating thrombotic diseases and cerebral ischemia diseases.

The present invention provides one kind of total paeonoside extract and its preparation process as well as the application of the total paeonoside extract in preparing medicine for preventing and treating cardiac and cerebral vascular diseases. Specifically, the total paeonoside extract is used in preparing medicine for preventing and treating cerebral apoplexy, cerebral ischemia/re-perfusion damabe, brain trauma, senile dementia, etc.

The invention provides a health product composition of bamboo leaf flavonoid and chitosan oligosaccharide. The preparation of the composition is an arbitrary pharmaceutically acceptable medicinal preparation, wherein the bamboo leaf flavonoid comprises pharmaceutically acceptable salt or solvate. According to the combination mode of the composition, bamboo leaf flavonoid and chitosan oligosaccharide are respectively prepared into independent preparations, and the two independent preparations are packaged in the same medicine box. The invention further provides a method for preparing the composition, application of the composition in preparation of medicines for resisting atherosclerosis, and application of the composition in preparation of medicines for improving myocardial ischemia and cerebral ischemia, protecting cardio and cerebral cells, reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases.

The invention relates to blended linseed oil and applications. The blended linseed oil is prepared from the following raw materials: linseed oil and other kinds of edible vegetable oil. The invention has the beneficial effects that (1) the blended linseed oil can prolong the shelf life of the linseed oil from 12 months to 18 months; (2) the taste of the blended linseed oil is better than the taste of the pure linseed oil; (3) the blended linseed oil has therapeutic effect, is suitable for patients with hyperlipoidemia (mainly hypertriglyceridemia), cardiovascular and cerebrovascular diseases and diabetes and middle and old aged people, is suitable for people with cardiovascular and cerebrovascular diseases and in a sub-health state, and is used for healthy people to prevent cardiovascular and cerebrovascular diseases; and (4) the blended linseed oil has a certain effect on relieving neurodegenerative diseases (ND) such as Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia (CI) and the like.